Back to products

Tivoxen 1.34 mg Capsule

Brand Name: Tivoxen

Molecule: Tivozanib

Strength: 1.34 mg

Quantity: 21 Capsules

Form: Capsule

Packaging Type: Bottle

Manufacturer/Marketed By: Everest Pharma

Country of Origin: Bangladesh

Description

Tivoxen Capsule contains Tivozanib, a targeted anti-cancer medicine used for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), specifically designed to block tumor growth by targeting blood vessel formation. Cancer cells require a continuous blood supply to grow and spread. Tivoxen works by inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are responsible for the formation of new blood vessels (angiogenesis). By blocking these receptors, the medicine effectively reduces blood supply to tumors, slowing their growth and progression. Tivoxen is typically prescribed for patients whose cancer has progressed after receiving previous treatments. It is taken orally, making it a convenient alternative to injectable cancer therapies. Clinical studies

Benefits

Targets cancer growth at the molecular level
Slows tumor progression by blocking blood supply
Improves progression-free survival in RCC patients
Oral therapy (more convenient than IV treatments)
Effective in patients with treatment-resistant cancer

Indications and Usage

Tivoxen (Tivozanib) is indicated for:

Advanced renal cell carcinoma (kidney cancer)
Relapsed or refractory RCC after prior treatments
Patients who have received two or more systemic therapies

How it Works

Tivozanib works by targeting specific proteins involved in tumor growth:

Inhibits VEGFR receptors (key drivers of angiogenesis)
Prevents formation of new blood vessels supplying tumors
Reduces tumor growth and spread

This targeted mechanism helps control cancer progression more precisely.

Dosage & Administration

Typical dose: 1.34 mg once daily
Taken for 21 days followed by 7 days off (28-day cycle)
Continue until disease progression or unacceptable toxicity
Can be taken with or without food
Capsules must be swallowed whole

Side Effects

Common side effects:

High blood pressure (hypertension)
Fatigue
Diarrhea
Decreased appetite
Nausea

Serious side effects:

Severe hypertension or hypertensive crisis
Heart problems (cardiac failure)
Blood clots
Bleeding complications
Protein in urine (proteinuria)

Patients should be closely monitored during treatment.

Warning and Precaution

Monitor blood pressure regularly
Risk of heart-related complications
Avoid use during pregnancy (may harm fetus)
Monitor kidney and liver function
Risk of bleeding and clotting disorders
Avoid drug interactions (e.g., herbal supplements like St. John’s Wort)

Patient Guidance

Take the medicine at the same time every day
Do not skip doses or double dose
Monitor blood pressure regularly
Report symptoms like severe headache, chest pain, or bleeding
Attend regular follow-up and blood tests
Avoid pregnancy during treatment

Clinical Trial & Approvals

Tivozanib is a globally recognized oncology drug:

Approved in the European Union (2017) and USA (2021)
Based on Phase III trials comparing it with other cancer therapies
Demonstrated improvement in progression-free survival in RCC patients
Studied in multiple international clinical trials

References

1. Tivozanib drug information (MedlinePlus)
➤ https://medlineplus.gov/druginfo/meds/a621018.html

2. Tivoxen product overview
➤ https://oncosolution.com/oncology/tivoxen-134-mg-tivozanib-capsule/

3. Tivozanib dosage & mechanism (SK Pharma)
➤ https://www.skpharmabd.com/product/tivoxen-1-34-mg-tivozanib/

4. Tivozanib clinical overview (Cleveland Clinic)
➤ https://my.clevelandclinic.org/health/drugs/23896-tivozanib-oral-capsules

5. Tivozanib clinical data & approval (Wikipedia)
➤ https://en.wikipedia.org/wiki/Tivozanib

Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies

The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another

May 18, 2026

Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important

May 14, 2026

FDA Fast-Tracks Plixorafenib for BRAF V600E–Mutated Brain Tumors

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade

April 14, 2026

Rated 0 out of 5

0 reviews

Rated 5 out of 5

Rated 4 out of 5

Rated 3 out of 5

Rated 2 out of 5

Rated 1 out of 5

Reviews

Clear filters

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.